Marrone Bio Innovations, Inc. discovers, develops, produces, and promotes biological products for pest management, plant nutrition, and plant health in the United States and internationally. Its products include Emergen, Foramin, Foramin ST, Pacesetter, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which are bio fungicides that protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide, which controls chewing and sucking insects and mites, as well as flies and plant parasitic nematodes; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. The company provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Davis, California.
IPO Year: 2013
Exchange: NASDAQ
Website: marronebio.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/22/2021 | $2.00 | Buy | Roth Capital |
8/19/2021 | $3.50 → $2.50 | Buy | Aegis Capital |
Roth Capital initiated coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $2.00
Aegis Capital reiterated coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $2.50 from $3.50 previously
Canaccord Genuity resumed coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $3.50
Canaccord Genuity reiterated coverage of Marrone Bio Innovations with a rating of and set a new price target of $3.50 from $2.00 previously
Aegis Capital reiterated coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $3.50 from $1.65 previously
15-12G - Pro Farm Group, Inc. (0001441693) (Filer)
EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)
EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)
EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)
EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)
EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)
S-8 POS - MARRONE BIO INNOVATIONS INC (0001441693) (Filer)
S-8 POS - MARRONE BIO INNOVATIONS INC (0001441693) (Filer)
S-8 POS - MARRONE BIO INNOVATIONS INC (0001441693) (Filer)
S-8 POS - MARRONE BIO INNOVATIONS INC (0001441693) (Filer)